Niloufar Mobashery

1.2k total citations
32 papers, 918 citations indexed

About

Niloufar Mobashery is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, Niloufar Mobashery has authored 32 papers receiving a total of 918 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hepatology, 22 papers in Epidemiology and 6 papers in Infectious Diseases. Recurrent topics in Niloufar Mobashery's work include Hepatitis C virus research (26 papers), Hepatitis B Virus Studies (16 papers) and Liver Disease Diagnosis and Treatment (14 papers). Niloufar Mobashery is often cited by papers focused on Hepatitis C virus research (26 papers), Hepatitis B Virus Studies (16 papers) and Liver Disease Diagnosis and Treatment (14 papers). Niloufar Mobashery collaborates with scholars based in United States, France and Germany. Niloufar Mobashery's co-authors include Claus Hélix‐Nielsen, O.S. Andersen, Rebecca Redman, Edward Tam, Christophe Hézode, Coleen Hall, Tarik Asselah, Edgar M. Carvalho, Roque Pacheco de Almeida and Paulo Roberto Lima Machado and has published in prestigious journals such as The Lancet, Gastroenterology and Clinical Infectious Diseases.

In The Last Decade

Niloufar Mobashery

32 papers receiving 906 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Niloufar Mobashery United States 15 638 595 192 180 120 32 918
Wangdon Yoo South Korea 10 609 1.0× 501 0.8× 223 1.2× 83 0.5× 97 0.8× 19 768
A. V. Kachko Russia 12 213 0.3× 227 0.4× 100 0.5× 51 0.3× 116 1.0× 31 451
Donna Pascual United States 10 285 0.4× 218 0.4× 162 0.8× 11 0.1× 131 1.1× 14 762
Alessandra Ceccacci Italy 7 357 0.6× 478 0.8× 275 1.4× 72 0.4× 146 1.2× 7 677
Krista Getty United States 9 295 0.5× 360 0.6× 496 2.6× 101 0.6× 317 2.6× 11 865
Shikha Shrivastava India 9 256 0.4× 117 0.2× 62 0.3× 197 1.1× 44 0.4× 26 462
Michele Bosserman United States 6 305 0.5× 420 0.7× 453 2.4× 96 0.5× 290 2.4× 6 792
José R. Oubiña Argentina 14 330 0.5× 306 0.5× 123 0.6× 40 0.2× 37 0.3× 47 489
Jose A. Garcia-Rivera United States 11 161 0.3× 185 0.3× 139 0.7× 24 0.1× 178 1.5× 18 426
Erik Helgstrand Sweden 9 315 0.5× 63 0.1× 210 1.1× 37 0.2× 210 1.8× 20 607

Countries citing papers authored by Niloufar Mobashery

Since Specialization
Citations

This map shows the geographic impact of Niloufar Mobashery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niloufar Mobashery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niloufar Mobashery more than expected).

Fields of papers citing papers by Niloufar Mobashery

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niloufar Mobashery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niloufar Mobashery. The network helps show where Niloufar Mobashery may publish in the future.

Co-authorship network of co-authors of Niloufar Mobashery

This figure shows the co-authorship network connecting the top 25 collaborators of Niloufar Mobashery. A scholar is included among the top collaborators of Niloufar Mobashery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niloufar Mobashery. Niloufar Mobashery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gogishvili, Miranda, Niloufar Mobashery, Tamta Makharadze, et al.. (2019). P2.01-26 EMPOWER-Lung 3: Phase 3 Study of Combinations of Cemiplimab and Chemotherapy in First-Line Treatment of Advanced NSCLC. Journal of Thoracic Oncology. 14(10). S649–S649. 4 indexed citations
2.
Zha, Jiuhong, Haoyu Wang, Chen Yu, et al.. (2018). Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients. European Journal of Drug Metabolism and Pharmacokinetics. 44(1). 43–52. 1 indexed citations
3.
Poordad, Fred, David R. Nelson, Jordan J. Feld, et al.. (2017). Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis. Journal of Hepatology. 67(4). 700–707. 7 indexed citations
4.
Asselah, Tarik, Christophe Hézode, Roula Qaqish, et al.. (2016). Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. ˜The œLancet. Gastroenterology & hepatology. 1(1). 25–35. 41 indexed citations
5.
6.
Hayashi, Norio, Makoto Nakamuta, Tetsuo Takehara, et al.. (2015). Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study. Journal of Gastroenterology. 51(4). 390–403. 15 indexed citations
7.
Lawitz, Eric, Mihály Makara, Ulus Salih Akarca, et al.. (2015). Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis. Gastroenterology. 149(4). 971–980.e1. 68 indexed citations
8.
9.
10.
Howe, A, Stuart Black, Stephanie Curry, et al.. (2014). Virologic Resistance Analysis From a Phase 2 Study of MK-5172 Combined With Pegylated Interferon/Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection. Clinical Infectious Diseases. 59(12). 1657–1665. 33 indexed citations
11.
Manns, Michael P., John M. Vierling, Bruce R. Bacon, et al.. (2014). The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis. Gastroenterology. 147(2). 366–376.e6. 28 indexed citations
12.
Hwang, Peggy, H. Campbell, Julie Strizki, et al.. (2013). 1198 RESISTANCE ANALYSIS OF CIRRHOTIC TREATMENT-EXPERIENCED GENOTYPE 1 PATIENTS IN A STUDY OF MK-7009 IN COMBINATION WITH PEGYLATED INTERFERON/RIBAVIRIN. Journal of Hepatology. 58. S487–S487. 2 indexed citations
13.
14.
Lawitz, Eric, Mark Sulkowski, Ira M. Jacobson, et al.. (2013). Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics. Antiviral Research. 99(3). 214–220. 26 indexed citations
15.
Rodríguez‐Torres, M., Albrecht Stoehr, Edward Gane, et al.. (2013). Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis. Clinical Gastroenterology and Hepatology. 12(6). 1029–1037.e5. 21 indexed citations
16.
Lawitz, Eric, M. Rodríguez‐Torres, Albrecht Stoehr, et al.. (2013). A phase 2B study of MK-7009 (vaniprevir) in patients with genotype 1 HCV infection who have failed previous pegylated interferon and ribavirin treatment. Journal of Hepatology. 59(1). 11–17. 29 indexed citations
17.
Chang, Andrew, Carl M. Kirsch, Niloufar Mobashery, Nancy Johnson, & Lee J. Levitt. (2004). Streptococcus bovis septic shock due to contaminated transfused platelets. American Journal of Hematology. 77(3). 282–286. 11 indexed citations
18.
Turetz, Meredith L., Paulo Roberto Lima Machado, Albert I. Ko, et al.. (2002). Disseminated Leishmaniasis: A New and Emerging Form of Leishmaniasis Observed in Northeastern Brazil. The Journal of Infectious Diseases. 186(12). 1829–1834. 143 indexed citations
19.
Almeida, Roque Pacheco de, Argemiro D’Oliveira, Paulo Roberto Lima Machado, et al.. (1999). Randomized, Double‐Blind Study of Stibogluconate Plus Human Granulocyte Macrophage Colony‐Stimulating Factor versus Stibogluconate Alone in the Treatment of Cutaneous Leishmaniasis. The Journal of Infectious Diseases. 180(5). 1735–1737. 39 indexed citations
20.
Mobashery, Niloufar, Claus Hélix‐Nielsen, & O.S. Andersen. (1997). The conformational preference of gramicidin channels is a function of lipid bilayer thickness1. FEBS Letters. 412(1). 15–20. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wangdon Yoo Breakdown of academic impact, for papers by A. V. Kachko Breakdown of academic impact, for papers by Donna Pascual Breakdown of academic impact, for papers by Alessandra Ceccacci Breakdown of academic impact, for papers by Krista Getty Breakdown of academic impact, for papers by Shikha Shrivastava Breakdown of academic impact, for papers by Michele Bosserman Breakdown of academic impact, for papers by José R. Oubiña Breakdown of academic impact, for papers by Jose A. Garcia-Rivera Breakdown of academic impact, for papers by Erik Helgstrand
Rankless by CCL
2026